IMPORTANCE Despite the absence of data from randomized clinical trials, professional societies recommend inferior vena cava (IVC) filters for patients with venous thromboembolic disease (VTE) and a contraindication to anticoagulation therapy. Prior observational studies of IVC filters have suggested a mortality benefit associated with IVC filter insertion but have often failed to adjust for immortal time bias, which is the time before IVC filter insertion, during which death can only occur in the control group.
Introduction
Venous thromboembolism (VTE), which includes both pulmonary embolism (PE) and deep vein thrombosis (DVT), is a significant cause of morbidity and mortality worldwide, with an incidence of 117 cases per 100 000 person-years 1 and a 1-year mortality for PE of at least 22% in patients with Medicare. 2 Treatment of patients with VTE is based on anticoagulation, but for many patients, this therapy is contraindicated owing to recent surgery or underlying coagulopathies. In patients with VTE and a contraindication to anticoagulation, major professional societies, including the American College of Chest Physicians, 3 American Heart Association, 4 Society of Interventional Radiology, 5, 6 American College of Radiology, 7 and the British Committee for Standards in Haematology 8 recommend consideration of IVC filter placement. While IVC filters have been widely available since the 1960s, their use in the United
States has steadily and dramatically increased from 2000 procedures in 1979 to more than 100 000 procedures in 2005. 9 More recently, rates have begun to decline with approximately 96 000 procedures in 2014. 10 This use has occurred despite the absence of data on a mortality benefit associated with IVC filter placement. An early randomized clinical trial showed a reduction in the number of symptomatic PEs but no reduction in mortality after IVC filter insertion. Importantly, this trial excluded patients with a contraindication to anticoagulant therapy, 11 which is, to our knowledge, the most widely accepted indication for IVC filter placement and the only indication for which the several professional societies agree. Retrievable IVC filters were analyzed in a randomized clinical trial 12 of patients with PE and a high likelihood of recurrence. In this trial, 12 IVC filters did not lower recurrent PE, but patients with a contraindication to anticoagulation were excluded. Thus, the findings of existing randomized clinical trials are not applicable to a large segment of the VTE population.
As a result, in the last 3 years, observational studies have attempted to understand the association between IVC filter placement in patients with VTE and a contraindication to anticoagulation and their outcomes. These studies have often failed to adjust for immortal time bias, which is the interval between hospital admission and IVC filter placement, during which time death cannot occur in the intervention group but can occur in the control group. 13 Failing to account for this potential source of bias can erroneously skew the results in favor of the intervention by falsely conferring a survival advantage to the treated group. 13 Given this concern for unaccounted biases in the context of a relatively common invasive procedure for which there is no evidence of a mortality benefit, we conducted an analysis incorporating adjustment for immortal time bias using 2 different statistical models to evaluate the outcomes of IVC filter placement in patients with VTE and a contraindication to anticoagulation. 
Methods

Primary Exposure, Outcomes, and Other Baseline Characteristics
During the index hospitalization, IVC filter insertion was identified by the ICD-9-CM procedure code 38.7. Comorbidities were identified using the Elixhauser classification 16 derived from the index hospitalization and admissions within the preceding year. Medical insurance (Medicare, Medicaid, private insurance, and other) and admission through the emergency department were identified at the index hospitalization.
Statistical Analysis
Our primary method of analysis was a multivariable Cox model with IVC filter status as a time- for individuals with and without IVC filter insertion. The primary outcome of interest was mortality at 30 days. Baseline characteristics of patients with and without IVC filter were compared using 2-sample t test for continuous variables and χ 2 test for categorical data. To account for any overdispersion, the Pearson χ 2 test was used to adjust standard errors via quasi-likelihood estimation. A 2-sided t test was used, and P < .05 was considered statistically significant. All analyses were conducted using SAS, version 9.3 and SAS Enterprise Guide, version 7.1 (SAS Institute Inc).
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Discussion
The most significant finding of this study of IVC filter use in patients with VTE and a contraindication to anticoagulation is that treatment with an IVC filter was associated with a higher 30-day mortality than treatment without IVC filter placement after adjustment for demographics, comorbidities, immortal times bias, and the propensity to receive a filter.
The initial long-term evaluation of IVC filter use was by Greenfield et al in 1981 17 and was expanded in the late 1980s 18 to include 469 patients. This study showed a 4% rate of PE in patients after placement of an IVC filter but had suboptimal follow-up and lacked a control group. Largely found that patients with VTE who were randomized to receive IVC filters experienced a reduction in symptomatic PE, no change in mortality, and an increased risk of recurrent DVT. Importantly, this trial excluded patients with a contraindication to anticoagulation, negating its applicability to the subset of patients in whom IVC filters are most universally recommended. The second study, 12 published in 2015, randomized 399 patients with PE and a high probability of recurrence to anticoagulation and a retrievable IVC filter vs anticoagulation alone. The outcomes of the 2 groups did not differ with respect to the primary outcome of recurrent PE or secondary outcomes including death or DVT at 3 for an invasive procedure is likely to involve selection bias whereby the sickest patients are considered too high risk for the procedure and are relegated to the control group, thus possibly confounding the results. This study attempts to expand on these findings by analyzing a diverse patient cohort including multiple states, patients with cancer, patients with a contraindication to anticoagulation, and patients who are and are not actively bleeding.
Limitations
Our findings should be interpreted within the context of several limitations. This study is retrospective and uses observational data derived from codes designed for reimbursement. A 2016 study proposed that the use of diagnostic codes from claims data can lead to an underestimation of event rates. 24 Furthermore, retrospective observational studies may be subject to various types of bias that persist despite various techniques to adjust for differences in baseline characteristics.
Therefore, these results should be considered hypothesis generating only. Second, this study only captured patient deaths during the index hospitalization, on a repeated admission or at a subsequent emergency department visit in the same state as the index hospitalization, thereby allowing for the possibility that some out-of-hospital or out-of-state deaths were not captured. However, there is no reason to believe these uncaptured events would occur more frequently in one group than in the other. Third, contraindications to anticoagulation span a range from minor relative contraindications to severe absolute contraindications. The lack of granularity of administrative data precludes the determination of the degree of absoluteness of any patient's contraindication to anticoagulation, whether therapeutic anticoagulation was attempted but required discontinuation, or if a patient was 
